Ποια είναι η τιμή για Genix Pharmaceuticals Corporation (GENPF)

Η τιμή για Genix Pharmaceuticals Corporation (GENPF) είναι $0.0138

Ποια είναι η κεφαλαιοποίηση αγοράς για Genix Pharmaceuticals Corporation (GENPF)

Η κεφαλαιοποίηση αγοράς για Genix Pharmaceuticals Corporation (GENPF) είναι $844.89K

Genix Pharmaceuticals Corporation (GENPF) Τιμή και Κεφαλαιοποίηση Αγοράς

Genix Pharmaceuticals Corporation, established in 1993 and headquartered in Vancouver, Canada, is actively involved in the creation, production, licensing, and distribution of various life science products. The company's primary focus in the Canadian market is on nutraceuticals and pharmaceuticals. Their product pipeline features several key developments: Flu-X: An herbal treatment available as an oral solution or spray, targeting viral infections, influenza, and coronaviruses responsible for common colds. Renochlor: A nutritional supplement formulated to support the revitalization and maintenance of kidney health and function. Sucanon: An insulin sensitizer designed to reduce blood sugar by improving the sensitivity of muscle, fat, and liver cells to insulin. Beyond these, Genix Pharmaceuticals also offers a wide range of other nutraceuticals and pharmaceutical items. This selection includes supplements such as bee propolis capsules, liquid calcium softgels, seal oil softgels, marine lipid softgels, lecithin softgels, fish oil softgels, EPO softgels, and spirulina powder, alongside ophthalmic products like eye ointments and drops. The company operated under the name Alta Natural Herbs & Supplements Ltd. until it adopted its current identity, Genix Pharmaceuticals Corporation, in June 2019.

Η τιμή για GENPF	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$88,917.75 $844.89K	NVDA	$5.444T	+644,331,414.83%
$73,237.51 $844.89K	AAPL	$4.484T	+530,706,503.69%
$68,053.20 $844.89K	GOOG	$4.166T	+493,139,038.26%
$60,436.77 $844.89K	MSFT	$3.700T	+437,947,512.19%
$46,363.80 $844.89K	AMZN	$2.839T	+335,969,492.38%

Η τιμή για GENPF

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$88,917.75 $844.89K